Proteonomix Inc. (OTCBB: PROT.OB), a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, announced further developments with its Joint Venture Company, XGEN Medical LLC (”XGen”) towards implementing operations in the United Arab Emirates (U.A.E.).

Proteonomix is the majority shareholder in XGen with the balance held by an anonymous investor group. (See, 17 August 2010 Press Release) Proteonomix personnel were on the ground in the U.A.E. over the past weeks to work together with the Investor Group through the start up phase. To date, XGen has established an office in the Monarch Office Tower on the prestigious Sheikh Zayed Road, and a residence for visiting Proteonomix personnel on Jumeira 2.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

****************************************

A new survey from Evolving Systems, Inc. (NASDAQ:EVOL) reveals the potential for European telecoms operators to tap into new revenue streams by delivering number choice and other personalized service offerings to prepaid customers.

The survey, carried out in spring 2010, polled the views and opinions of 500 prepaid mobile phone subscribers across the UK, France, Germany, Italy and Spain.

More than 30% of respondents in each country said they would be prepared to pay a premium for the ability to select their own number - depending on cost. The proportions are highest in France (45%) and Italy (43%).

Of those users who stated they would be prepared to pay a premium, around 25% said that they would pay between EUR 6-50 (between £6 and £50 in the case of UK users). France had the most engaged set of respondents in this respect with 31% fitting into this category.

“These figures will give wireless operators food for thought,” says Evolving Systems’ Chief Technology Officer Stuart Cochran. “If operators could convert these percentages of their prepaid mobile subscriber base to number personalization, they would gain a significant incremental revenue source. There clearly is a potential market in these key European countries for personalized number selection and it is equally clear that this market remains largely unexploited so far.”

The survey finds that only a small proportion of prepaid users have ever been offered the opportunity to select their own mobile number. Just 13% of prepaid French users (and only 21% of those in Italy), for example, had been given this option when buying a prepaid SIM card.

*********************************************

Exact Sciences Corp. (Nasdaq: EXAS) just recently announced that it will present at the 2010 William Blair & Company Emerging Growth Stock Conference, which is being held Oct. 5, 2010, at the InterContinental New York Barclay Hotel in New York.

Kevin T. Conroy, Exact’s president and chief executive, will make the company’s presentation at 4:15 p.m. Eastern Time. A live webcast of the presentation will be available through the company’s website at www.exactsciences.com. An archived webcast will be available following the conclusion of the conference.

**********************************************

Exactech, Inc. (NasdaqGS: EXAC)

Exactech Inc., which makes bone and joint restoration products, said Friday it acquired several spine product lines from the privately held medical device company VertiFlex Inc.

Terms of the deal were not disclosed.

Exactech, which is based in Gainesville, Fla., said VertiFlex develops minimally invasive, motion-preserving spinal surgery technologies that fit well with its portfolio of spine products. That includes several cervical and lumbar fusion products.

Sign up for free stock alerts at http://www.pennygovernance.com/signup

***************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyGovernance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyGovernance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more @ http://pennygovernance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading share from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

***************************************